E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The study is focused on asthma bronchiale and chronic obstructive pulmonary disease (COPD) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10003553 |
E.1.2 | Term | Asthma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of the study is to assess intrapulmonary deposition of Foster. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objective is to describe intrapulmonary distribution, pharmacokinetic properties of the drug formulation and evaluation of the lung function. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Healthy subjects: 1. Age 21 - 70 2. Ability to properly use the pMDI 3. Body Mass Index (BMI) between 18.0 and 30 kg/m2 4. Normal blood pressure and heart rate (supine SBP 100-150 mmHg, supine DBP 50-90 mmHg, heart rate 50-90 bpm) 5. Electrocardiogram (12 lead) with computerized protocol interpretation considered as normal (120 ms≤PR≤220ms, QRS≤120ms, QTc≤450ms). 6. Non-smokers or ex-smokers with a smoking history of less than 5 pack- years and stopped smoking at least one year ago. 7. written informed consent
Patients with Asthma: 1. Age 21 - 70 2. Ability to properly use the pMDI 3. Body Mass Index (BMI) between 18.0 and 30 kg/m2 4. Normal blood pressure and heart rate (supine SBP 100-150 mmHg, supine DBP 50-90 mmHg, heart rate 50-90 bpm). 5. Electrocardiogram (12 lead) with computerized protocol interpretation considered as normal (120 ms≤PR≤220ms, QRS≤120ms, QTc≤450ms). 6. Patients with moderate persistent or severe persistent Asthma according to the GINA Classification of Asthma Severity by Daily Medication Regimen and Response to Treatment. 7. FEV1 ≥ 30% and < 80% of predicted for the patient’s normal value (according to the predicted value for spirometric function, European Coal and Steel Community values) measured at least 8 hours after the last use of short-acting β2-agonist bronchodilators or short-acting anticholinergics, 72 hours after the last use of long-acting β2- agonist bronchodilators and 72 hours after the last use of long-acting anticholinergics. 8. Reversibility of FEV1 ≥ 12% and at least 200 ml of the initial value 30 minutes after inhalation of 200 mcg Salbutamol within the screening period 9. In good health on the basis of a medical history, physical examination, clinical laboratory studies and ECG with the exception of Asthma 10. Non-smokers or ex-smokers with a smoking history of less than 5 pack- years (e.g. < 20 cigarettes per day for 5 years or 40 cigarettes per day for 2.5 years) and stopped smoking at least 1 year ago. 11. written informed consent
Patients with COPD: 1. Age 40 - 70 2. Ability to properly use the pMDI 3. Body weight resulting in a Body Mass Index (BMI) between 18.0 and 30 kg/m2 4. Normal blood pressure and heart rate (supine SBP 100-150 mmHg, supine DBP 50- 90 mmHg, heart rate 50-90 bpm). 5. Electrocardiogram (12 lead) with computerized protocol interpretation considered as normal (120 ms≤PR≤220ms, QRS≤120ms, QTc≤450ms). 6. Stable COPD 7. Decreased FEV1 between 30% and 50% predicted values (30% ≤FEV1 < 50%) measured at least 8 hours after the last use of short-acting β2- agonist bronchodilators or short-acting anticholinergics, 72 hours after the last use of long-acting β2-agonist bronchodilators and 72 hours after the last use of long-acting anticholinergics. 8. FEV1/Forced Vital Capacity (FEV1/FVC) ≤ 70% documented at screening visit 9. Reversibility of FEV1 < 12 % of the initial value 30 minutes after inhalation of 200µg Salbutamol within the screening period 10. Treatment with any COPD medication at a constant dosage during the last 4 weeks prior to inclusion 11. Minimum smoking history of 10 pack-years (pack-years = the number of cigarette packs per day times the number of years) 12. written informed consent
|
|
E.4 | Principal exclusion criteria |
All subjects: 1. Blood donation (equal or more than 450 ml) or blood loss less than 8 weeks before the first intake of study drug 2. Positive HIV1 or HIV2 serology 3. Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C 4. Unsuitable veins for repeated venipuncture 5. Female patients: pregnant, positive pregnancy test, lactating mother or lack of efficient contraception (according to CPMP/ICH 286/95 note 3 ). Postmenopausal women < 1 year must have efficient contraception 6. History of substance abuse or drug abuse within 12 months or with a positive urine drug screen 7. Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical investigation 8. Clinically significant and uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol 9. Participation in an investigational drug study within 30 days prior to Visit 1 or current participation in another investigational drug study 10. Known sensitivity to Formoterol or Beclomethasone or any of the excipients contained in any of the formulations used in the trial. 11. Concomitant severe diseases or diseases which are contra indications for the use of inhaled 2-agonist or steroids. 12. Use of any prescription drug for which concomitant beta-agonist or steroid administration are contraindicated. 13. History of significant sensitivity, allergy or intolerance to study drug formulation ingredients. 14. Recent relevant infectious disease (less than two months) 15. Flu vaccination within 4 weeks prior to the screening visit 16. Other vaccination within 4 weeks prior to the screening visit
Additional exclusion criteria for patients with Asthma: 1. Use of systemic steroids 4 weeks prior to inclusion (injectable depot steroids 6 weeks) or more than 3 periods during the last 6 months 2. Life-threatening/unstable respiratory status including upper or lower respiratory tract infection, within the previous 30 days 3. Requirement of continuous supplemental oxygen therapy; the use of supplemental oxygen not exceeding 2l/min, at night time only and/or only during exercise is allowed 4. Change in dose or type of any medications for asthma within 4 weeks prior to the screening visit 5. Asthma exacerbation within the 4 weeks prior to inclusion
Additional exclusion criteria for patients with COPD: 1. Use of systemic steroids 4 weeks prior to inclusion (injectable depot steroids 6 weeks) or more than 3 periods during the last 6 months 2. Life-threatening/unstable respiratory status including upper or lower respiratory tract infection, within the previous 30 days 3. Requirement of continuous supplemental oxygen therapy; the use of supplemental oxygen not exceeding 2l/min, at night time only and/or only during exercise is allowed 4. Change in dose or type of any medications for COPD within 4 weeks prior to the screening visit 5. COPD exacerbation within the 4 weeks prior to inclusion 6. History of asthma or any chronic respiratory diseases other than COPD
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Intrapulmonary deposition |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
lung deposition measurement |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 6 |